Anne Osdoit

    Partner, MD Start Strategy

    Anne has been running our in-house MedTech accelerator, MD Start, since she came on board as a partner in 2015.

    She embodies the MD Start team’s hands-on approach: Anne is the founding and current CEO of both Gradient Denervation Technologies and Moon Surgical. She is a Board member of both SafeHeal and AblaCare — two companies where she was also founding CEO.

    “What I like about this job is that it is about building products and companies,” Osdoit says. “It is very diverse. It is in different therapeutic areas, in different spaces with different technologies.”

    Prior to joining Sofinnova, Anne held several key positions at Mauna Kea Technologies, a Paris-based medical technology company with global presence, developing a disruptive “optical biopsy” technology. She was closely involved in multiple financing rounds, including the company’s initial public offering on the Paris Euronext, a highly successful operation and the largest public listing for the sector that year.

    Anne is an active angel investor and an independent board member of FeetMe and Cardiologs Technologies, two Paris-based e-health startups. Cardiologs was purchased by Philips in 2021.

    Anne is a trained biomedical engineer from Ecole Polytechnique of Paris, France and Johns Hopkins University in Baltimore, Maryland. She holds additional degrees in Biostatistics and epidemiology applied to clinical trials (Université Pierre et Marie Curie), as well as Corporate Finance (London School of Economics).


    “We’re not trying to find ways to use new technologies in medicine. We start from the clinical need. From there, we try to find technologies that will help us develop products that are going to solve that need.”

    Sector

    Medical Devices

    Related companies

    Join our mailing list

    Keep up to date with our latest news.

    Required
    Thanks for submitting the form. You are now subscribed to Sofinnova Partners news alerts.An error happened. Please try again later.